HK1214139A1 - 用於癌症治療的具有減弱的對 抗體的交叉反應性的精氨酸脫亞胺酶 - Google Patents

用於癌症治療的具有減弱的對 抗體的交叉反應性的精氨酸脫亞胺酶

Info

Publication number
HK1214139A1
HK1214139A1 HK16102073.8A HK16102073A HK1214139A1 HK 1214139 A1 HK1214139 A1 HK 1214139A1 HK 16102073 A HK16102073 A HK 16102073A HK 1214139 A1 HK1214139 A1 HK 1214139A1
Authority
HK
Hong Kong
Prior art keywords
adi
peg20
antibodies
cancer treatment
peg
Prior art date
Application number
HK16102073.8A
Other languages
English (en)
Inventor
Robert Almassy
Richard E Showalter
James A Thomson
Wes Sisson
Wei-Jong Shia
Li-Chang Chen
Yang Lee
Original Assignee
Polaris Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polaris Group filed Critical Polaris Group
Publication of HK1214139A1 publication Critical patent/HK1214139A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK16102073.8A 2013-03-15 2016-02-24 用於癌症治療的具有減弱的對 抗體的交叉反應性的精氨酸脫亞胺酶 HK1214139A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790833P 2013-03-15 2013-03-15
PCT/US2014/026766 WO2014151982A2 (en) 2013-03-15 2014-03-13 Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment

Publications (1)

Publication Number Publication Date
HK1214139A1 true HK1214139A1 (zh) 2016-07-22

Family

ID=51581665

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16102073.8A HK1214139A1 (zh) 2013-03-15 2016-02-24 用於癌症治療的具有減弱的對 抗體的交叉反應性的精氨酸脫亞胺酶
HK16107312.8A HK1219232A1 (zh) 2013-03-15 2016-06-23 用於癌症治療的具有減弱的對 抗體的交叉反應性的精氨酸脫亞胺酶

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16107312.8A HK1219232A1 (zh) 2013-03-15 2016-06-23 用於癌症治療的具有減弱的對 抗體的交叉反應性的精氨酸脫亞胺酶

Country Status (13)

Country Link
US (2) US11235037B2 (zh)
EP (2) EP2968482B1 (zh)
JP (1) JP6382934B2 (zh)
KR (2) KR102455753B1 (zh)
CN (1) CN105188739B (zh)
AU (1) AU2014236653B2 (zh)
BR (1) BR112015021483A2 (zh)
CA (1) CA2901795C (zh)
ES (1) ES2805360T3 (zh)
HK (2) HK1214139A1 (zh)
RU (1) RU2015141932A (zh)
SG (1) SG11201507354QA (zh)
WO (1) WO2014151982A2 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782653A1 (en) 2012-04-04 2021-02-24 Polaris Group Composition comprising pegylated arginine deiminase
BR112015021483A2 (pt) 2013-03-15 2017-10-10 Polaris Group arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
EP3119421B1 (en) 2014-03-18 2019-10-02 TDW Group Engineered chimeric pegylated adi and methods of use
WO2016007625A1 (en) 2014-07-08 2016-01-14 Tdw Group Antibodies to argininosuccinate synthase and related methods
SG10202002557SA (en) * 2014-09-16 2020-04-29 Tdw Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
TWI699210B (zh) * 2015-03-18 2020-07-21 開曼群島商瑞華藥業集團 工程化之嵌合聚乙二醇化ａｄｉ及使用方法
TWI784982B (zh) * 2016-11-02 2022-12-01 開曼群島商北極星藥業集團股份有限公司 聚乙二醇化精胺酸脫亞胺酶之調配物
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
CN108324951B (zh) * 2018-04-16 2021-05-25 薛剑峰 一种精氨酸脱亚胺酶注射剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
US5804183A (en) 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6635462B1 (en) 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6180387B1 (en) 1997-08-11 2001-01-30 Smithkline Beecham Corporation Arginine deiminase
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
WO2002009741A1 (en) * 2000-07-27 2002-02-07 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
KR20040004449A (ko) 2000-11-28 2004-01-13 휘닉스 파머컬러직스, 인크. 변형된 아르기닌 데이미나제
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
ES2477118T3 (es) * 2002-11-18 2014-07-15 Polaris Group Método para inhibir la replicaci�n viral in vivo
EP1629119A2 (en) 2003-04-29 2006-03-01 Wyeth Methods for diagnosing aml and mds by differential gene expression
WO2005052145A2 (en) 2003-10-07 2005-06-09 University Of Florida Recombinant alkaliizing bacteria
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
US20100197944A1 (en) 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
US20090238813A1 (en) * 2007-12-28 2009-09-24 Board Of Regents, The University Of Texas System Compositions And Methods For Engineered Human Arginine Deiminases
US20120015049A1 (en) 2009-01-14 2012-01-19 Lin Zhang Microrna biomarker in cancer
US20110111403A1 (en) * 2009-10-30 2011-05-12 Life Technologies Corporation Multi-primer assay for mycoplasma detection
AU2011260016B2 (en) 2010-06-02 2013-08-22 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of Rapamycin esters
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
PL394618A1 (pl) 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
FR2978416B1 (fr) 2011-07-26 2013-11-29 Decathlon Sa Vehicule, par exemple du type trottinette, avec systeme de repliage
US8663967B2 (en) 2011-08-22 2014-03-04 Jiangsu T-Mab Biopharma Co., Ltd. Arginine deiminase mutant and preparation and application thereof
EP3782653A1 (en) 2012-04-04 2021-02-24 Polaris Group Composition comprising pegylated arginine deiminase
BR112015021483A2 (pt) 2013-03-15 2017-10-10 Polaris Group arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
EP3119421B1 (en) 2014-03-18 2019-10-02 TDW Group Engineered chimeric pegylated adi and methods of use
SG10202002557SA (en) 2014-09-16 2020-04-29 Tdw Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Also Published As

Publication number Publication date
US20220105160A1 (en) 2022-04-07
KR102263038B1 (ko) 2021-06-14
EP2968482B1 (en) 2020-05-06
EP3744341A1 (en) 2020-12-02
RU2015141932A (ru) 2017-04-26
HK1219232A1 (zh) 2017-03-31
KR20210069126A (ko) 2021-06-10
CA2901795C (en) 2022-08-02
CA2901795A1 (en) 2014-09-25
BR112015021483A2 (pt) 2017-10-10
JP6382934B2 (ja) 2018-08-29
US11235037B2 (en) 2022-02-01
ES2805360T3 (es) 2021-02-11
KR20150129728A (ko) 2015-11-20
JP2016519069A (ja) 2016-06-30
AU2014236653A1 (en) 2015-09-10
WO2014151982A3 (en) 2015-01-08
US20140348814A1 (en) 2014-11-27
CN105188739B (zh) 2017-06-23
SG11201507354QA (en) 2015-10-29
EP2968482A2 (en) 2016-01-20
EP2968482A4 (en) 2016-07-20
AU2014236653B2 (en) 2019-04-18
KR102455753B1 (ko) 2022-10-17
CN105188739A (zh) 2015-12-23
WO2014151982A2 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
IL292193A (en) Anti-b7–h1 antibodies for the treatment of tumors
HRP20190502T1 (hr) Afukozilirana anti-fgfr2iiib protutijela
HK1214139A1 (zh) 用於癌症治療的具有減弱的對 抗體的交叉反應性的精氨酸脫亞胺酶
IL240024A0 (en) Polystatin in the treatment of Duchenne muscular dystrophy
EP2849785A4 (en) METHOD FOR THE TREATMENT OF CANCER WITH NOTCH2 / 3 ANTIBODIES
SG11201702103XA (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
EP2956853A4 (en) SOFTWARE PIPELINING DURING TIME
IL235369B (en) Anti-transglutaminase 2 antibodies
GB201411291D0 (en) Processing transactions
EP2980215A4 (en) MODIFIED GLYCINE OXIDEASE
IL236714A0 (en) Anti-her2 antibodies with reduced fucosylation for use in cancer therapy
HUE056609T2 (hu) NOTCH1-re specifikus SIRNS-molekulák
EP2947462A4 (en) SAMPLE PROCESSING SYSTEM
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
ZA201504169B (en) Anti-adam28 antibody for treating cancer
EP2927243A4 (en) ANTI-VASOHIBIN ANTIBODY-2
EP2972355A4 (en) FLUORGENIC BIOSENSORS WITH NETWORKED PEPTIDES
GB201414684D0 (en) Major branch instructions with transactional memory
GB201302700D0 (en) Compiler
GB201304811D0 (en) Novel treatment for hypertension
TH1501001800A (th) โครงย่อยสำหรับส่วนลำตัวลิ้น